Track market-moving stories before they get noisy

Baby boomers heading into retirement face a specific math problem: They need income that grows faster than inflation, drawn from businesses stable enough to survive whatever the next decade throws at them. With the 10-Year Treasury yielding 4.56% as of July 10, 2026 and Core PCE inflation still climbing (index at 130.08 in May 2026, up 0.3% month over month), fixed-rate bonds alone will not preserve purchasing power over a 25-year retirement. Dividend Kings, companies with 50-plus years of consecutive dividend hikes, remain the workhorse solution.

Here are three durable-income names built for the long haul, each with a specific bull case and a risk worth respecting.

Johnson & Johnson (JNJ) Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is the healthcare anchor almost every retirement portfolio needs. The company just posted Q1 2026 revenue of $24.06 billion (up 9.9% year over year) and adjusted EPS of $2.70, both ahead of Street expectations, and management raised FY2026 guidance to revenue of $100.3 billion to $101.3 billion and adjusted EPS of $11.45 to $11.65.

The dividend track record is the headline. The board approved a 3.1% dividend increase to $1.34 per share quarterly, marking 64 consecutive years of dividend growth, verified by the payment record showing the Q2 2026 ex-dividend date of May 26, 2026 at $1.34 versus $1.30 the prior quarter. The annualized forward payout of $5.36 gives retirees a concrete income figure to plan around.

Growth is accelerating too. DARZALEX delivered $3.96 billion in the quarter (up 22.5%), TREMFYA grew 68.3%, and CARVYKTI expanded 62.1%. CEO Joaquin Duato called this “a strong start to 2026” delivering on the promise of “a year of accelerated growth and impact.” Shares reflect that momentum: JNJ is up around 52% over the past year and 23.23% year to date through July 22, with a beta of 0.235 that still qualifies as defensive.

Risk/caveat: STELARA biosimilar erosion hit hard, with sales down 59.7% to $656M, and the planned Orthopaedics separation carries execution risk. At a forward P/E near 22, this is no longer a bargain-bin buy.

Kimberly-Clark (KMB) Kimberly-Clark (NASDAQ:KMB) is the consumer-staples version of this trade: Huggies, Kleenex, Scott, Kotex, Cottonelle, Poise and Depend all sit in cabinets that get restocked whether the economy is booming or contracting.

The Q1 2026 print was solid: adjusted EPS of $1.97, which beat the $1.93 estimate, on revenue of $4.16 billion. The company reaffirmed 2026 guidance for organic sales growth of ~2.5% and double-digit adjusted EPS growth on a constant-currency basis, with International Personal Care up 9.1% to $1.51 billion.

The dividend? The Q1 2026 quarterly rose to $1.28 from $1.26 in Q4 2025, extending a streak the data confirms has run every single year from 1999 through 2026. The 4.7% trailing yield is one of the highest available in blue-chip staples.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn't make the cut. Grab the names FREE today.

Valuation looks reasonable too: forward P/E of 15 versus a trailing 22, with a beta of 0.279. CEO Mike Hsu framed the pending Kenvue acquisition as a “generational value creation opportunity.” For retirees hunting income, this is a Dividend King built to weather cycles.

If maximizing income across a full portfolio is the objective, 24/7 Wall St.’s 10 Dividend Kings research report drills into how these multi-decade compounders fit alongside other steady-payer names.

Risk/caveat: Reported net sales fell 14% year over year due to IFP discontinued operations and the US private label diaper exit, and the consumer tissue restructuring plus Kenvue integration risk are real. As of July 22, shares are down 15.52% over the past year — a reminder that even Kings have off years.

Genuine Parts Company (GPC) Genuine Parts Company (NYSE:GPC) owns NAPA Auto Parts and one of the strongest industrial distribution networks in North America. Q1 2026 delivered adjusted EPS of $1.77, revenue of $6.26B (up 6.8% YoY), and comparable sales up 2.4%. Management reaffirmed FY2026 guidance for sales growth of 3% to 5.5%, adjusted diluted EPS of $7.50 to $8 and free cash flow of $550 million to $700 million.

The dividend streak here is the longest of the three. Data confirms 70 consecutive years of dividend increases announced with Q4 2025, with the annual rate up 3.2% to $4.25 per share. Payment records verify the Q1 2026 quarterly at $1.0625 (up from $1.03 through 2025), annualized forward of $4.25, with the latest payment on July 2, 2026. The 3.53% yield gives income a running start, and the planned tax-free separation into Global Automotive and Global Industrial businesses is targeted for Q1 2027, which could unlock trapped value.

CEO Will Stengel noted the team “delivered first quarter results ahead of expectations” while progressing on the separation.

Risk/caveat: Q4 2025 posted a GAAP net loss of $609.5 million driven by a $742 million pension settlement charge and a $150.5 million First Brands supplier bankruptcy credit loss. Add tariff exposure, separation execution risk, and a Q1 2026 free cash flow deficit of $33.6 million and the near-term picture is choppier than the streak suggests.

The Bottom Line All three names are Dividend Kings in defensive sectors, and all three have raised payouts through recessions, wars, and rate cycles. For baby boomers building an income base to draw from for decades, that consistency is the point. The forward-looking question is whether each company can navigate its current transition (JNJ’s Orthopaedics spin, KMB’s Kenvue integration, and GPC’s separation) without disrupting cash flow to shareholders. History says the odds favor the Kings.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.

As of market close on July 7, the S&P 500 (^GSPC 0.42%) and Nasdaq Composite (^IXIC 0.23%) are up 9.6% and 11.1% year to date (YTD), respectively, and hovering around all-time highs. The tech sector -- which makes up 38% of the index -- is largely responsible for the strong gains because it is up 24.5% YTD.

However, some noteworthy value stocks are doing even better than the tech-heavy S&P 500. Kimberly-Clark (KMB 2.75%) is up 13.7% YTD, and that's without even factoring in two $1.28 per share dividend payments. Earlier this year, Kimberly-Clark raised its dividend for the 54th consecutive year, retaining its spot on the list of Dividend Kings, which have at least 50 consecutive years of dividend increases.

Here's why Kimberly-Clark remains a great dividend stock to buy for the second half of the year.

Image source: Getty Images.

1. Kimberly-Clark is recession-resistant Kimberly-Clark has a portfolio of leading household and personal care brands, many of which are paper-based. Its crown jewel is Huggies, which is the No. 2 diaper brand in the world behind Pampers. Other notable brands include Kleenex, Kotex, Scott, and Cottonelle.

Demand for these products tends to be consistent across economic cycles, though Kimberly-Clark's margins have been under pressure due to rising costs and inflationary pressures on consumer spending. In Kimberly-Clark's first-quarter 2026 earnings call, it forecasted $150 million to $170 million in additional costs if oil remained around $100 per barrel. Oil prices have come down significantly since that late April earnings call, but the months when oil was elevated will affect its full-year margins.

However, Kimberly-Clark is implementing productivity initiatives, new pricing with suppliers, and hedging programs to improve margins. Kimberly-Clark's chief financial officer, Nelson Urdaneta, said the following on the Q1 2026 earnings call:

I'd also remind everyone that we've got a solid track record over the last four years of recovering any input cost inflation and actually expanding margins. If you look at 2023 through 2025, we expanded both gross margins and operating profit margins beyond the levels pre-pandemic. So we're confident in our ability to cover all these input costs over time.

Kimberly-Clark isn't immune to consumer spending trends or macroeconomic factors, but it has done a good job adjusting to the new normal of cost inflation.

Today's Change

(

-2.75

%) $

-3.16

Current Price

$

111.58

2. A major acquisition is right around the corner In November 2025, Kimberly-Clark announced the acquisition of Kenvue (KVUE 1.80%). The consumer health company spun off from Johnson & Johnson in August 2023 and owns many noteworthy brands, including Aveeno, Neutrogena, Tylenol, Listerine, Johnson's, and BAND-AID.

Since then, Kimberly-Clark and Kenvue shareholders have overwhelmingly approved the acquisition, and Kimberly-Clark has moved forward with key organizational and leadership decisions.

The deal will diversify Kimberly-Clark's revenue streams and enhance its resilience in a recession. Kimberly-Clark expects the transaction to close before the end of the year.

3. Kimberly-Clark is dirt cheap You may think that Kimberly-Clark would command a premium valuation, given that its stock price is outpacing the S&P 500 and Nasdaq in 2026. However, Kimberly-Clark fell 23% last year and is down 18.1% over the last decade.

Kimberly-Clark now trades at just 15.2 times analyst consensus 2026 earnings estimates of $7.54 per share. Its 10-year median price-to-earnings ratio is 21.9.

A top high-yield dividend stock to buy now Investors who believe the Kenvue acquisition is the right move are getting a chance to buy Kimberly-Clark at a dirt cheap valuation. Kimberly-Clark expects the combined company to deliver $2.1 billion in annual run rate synergies by the second year following the acquisition, unlocking operating leverage and boosting margins.

In the meantime, investors can count on Kimberly-Clark's high-yield dividend. Although a high yield can sometimes indicate that a dividend is becoming unsustainable, Kimberly-Clark's earnings and free cash flow still exceed its payout.

With an established and recession-resistant portfolio of brands, Kimberly-Clark stands out as an attractive value stock for investors looking for an alternative to high-flying growth stocks. Unlike hyperscaler cloud computing companies, Kimberly-Clark isn't spending a ton of capital expenditures on big ideas that it needs to pay off. Rather, it is a stable stalwart that has rewarded income investors for decades.

Therefore, Kimberly-Clark can continue to outperform the S&P 500 and Nasdaq because its earnings growth expectations are already low. So even decent results would likely be received well by investors. However, Kimberly-Clark isn't without its risks.

If the Kenvue acquisition doesn't go as smoothly as planned or fails to unlock the cost savings Kimberly-Clark hopes for, it could make its dividend less affordable, which could strain its balance sheet. The combined company must also prove it can extract value from a larger portfolio of brands, which comes with a slew of execution challenges from a new leadership team.

Therefore, some investors may want to wait for the dust to settle after the Kenvue acquisition before buying the stock. Investors who don't mind the uncertainty can scoop up shares at an attractive valuation.

Kimberly-Clark (NASDAQ:KMB | KMB Price Prediction) just sent another check to shareholders, and the math is making conservative income investors nervous. The consumer staples giant paid out $1.28 per share on July 2, 2026, marking another quarter in a dividend streak that now stretches more than five decades. The problem? On certain adjusted measures, the payout ratio is hovering near 80%, and free cash flow barely covered the dividend last year. For retirees who depend on this Dividend Aristocrat for income, that’s the kind of data point that triggers a portfolio review.

However, if you dig into the balance sheet, a very different story emerges. Kimberly-Clark is actively deleveraging, equity is rebuilding at a pace not seen in years and operating cash flow just exploded in the most recent quarter. The dividend sits on a wider beam than the trailing payout ratio suggests.

The Payment That Sparked the Debate The Q1 2026 declaration lifted the quarterly rate to $1.28 from $1.26, extending Kimberly-Clark’s growth streak to 53 consecutive years of annual increases. At the current price of $110.06, that puts the trailing dividend yield at 5%, well above the broader market and competitive with investment-grade corporate bonds.

The annualized run rate sits at $5.12 per share for 2026, up from $5.04 in 2025 and $4.88 in 2024. The progression has been remarkably mechanical: small, predictable raises that prioritize the streak over flash.

Why Retirees Are Worried: The Coverage Math The case against Kimberly-Clark starts with one statistic that should make any dividend investor pause. In fiscal 2025, the company generated $1.639 billion in free cash flow against $1.660 billion in dividend payments. That’s a coverage ratio of 0.99x, the first time in a decade that free cash flow has not comfortably covered the distribution.

Historical context makes the deterioration look sharper. From 2016 through 2024, free cash flow coverage typically ran between 1.4x and 1.9x. The driver was capital intensity. Capital expenditures jumped to $1.138 billion in 2025 from $721 million in 2024, consuming 41% of operating cash flow, the highest ratio in the 10-year period.

Q1 2026 looks tighter still when isolated. Free cash flow of $321 million fell short of the $418 million dividend payment. Buybacks also pulled back hard: share repurchases dropped to $141 million in 2025 from $1.0 billion in 2024. Management is clearly prioritizing the dividend, which is exactly what raises the question of whether something has to give.

The Balance Sheet Counter-Argument Here’s where the bear case starts breaking down. While free cash flow tightened, Kimberly-Clark used 2025 to materially strengthen its capital structure.

Shareholder equity rose to $1.502 billion at year-end 2025 from $840 million in 2024, a 79% jump. Total debt fell by $620 million to $7.296 billion. The debt-to-equity ratio improved from 9.42x to 4.86x in a single year. By the end of Q1 2026, equity had climbed further to $1.796 billion while total debt continued to drift down to $7.084 billion.

Retained earnings of $9.611 billion provide a substantial accumulated cushion. That’s the profile of a company simultaneously paying down debt, raising distributions, and reinvesting in capacity.

Q1 2026 Cash Flow Tells a Different Story The single most underappreciated data point in this debate is the operating cash flow swing in the latest quarter. Q1 2026 operating cash flow came in at $745 million, up 128% year over year. That’s the kind of working capital release that doesn’t happen at companies on the verge of cash distress.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Kimberly-Clark didn't make the cut. Grab the names FREE today.

Earnings followed the same path. Adjusted EPS of $1.97 beat the $1.93 consensus, the fourth consecutive quarterly beat. Revenue of $4.163 billion topped expectations, and net income jumped 17% year over year to $665 million. The International Personal Care segment posted 9% revenue growth with operating profit up 22%.

CEO Mike Hsu framed the quarter directly: “Our first quarter results highlight the strength and resilience of the growth engine we’ve built through Powering Care…[and] we continue to generate meaningful cost savings that reinforce our strong financial foundation and enable us to invest in our exciting future.”

Dividend Scorecard Metric Value Assessment Current Yield 5% Premium income Consecutive Growth Years 53 Dividend Aristocrat tier Payout Ratio (GAAP EPS) ~67% Elevated but workable FCF Coverage (FY 2025) 0.99x Tight Debt-to-Equity 4.86x Improving sharply Beta 0.302 Low volatility Latest Raise $1.26 to $1.28 On schedule Grade: B+

The free cash flow squeeze is real and worth monitoring, but balance sheet repair, the 27-year uninterrupted payment record, and the operating cash flow acceleration in Q1 2026 outweigh the trailing coverage concern. A pure A would require restored FCF coverage above 1.3x.

The Macro Backdrop Favors the Dividend Retirees evaluating Kimberly-Clark aren’t doing so in a vacuum. The savings rate has compressed to 4% in Q1 2026 from 6% in Q1 2024, suggesting income-dependent households are drawing down reserves. Per-capita disposable income has climbed to $68,391, but Social Security receipts of $1.630 trillion now anchor retiree budgets more than ever.

Demand for Kimberly-Clark’s core categories has held up. Spending on the “Other” nondurable goods category, which captures personal care and household products, ran at $1,810.8 billion in May 2026 versus $1,714.6 billion in May 2025. Tissue, diapers, and feminine care are textbook recession-resistant categories, and the BEA data shows consumers continuing to spend on them through a softening savings environment.

The Kenvue Wild Card Looming over everything is the pending $48.7 billion Kenvue (NYSE:KVUE) acquisition, which shareholders have already approved. Integration risk is real, but so is the strategic logic of combining Kimberly-Clark’s distribution muscle with Kenvue’s branded consumer health portfolio. The IFP joint venture with Suzano (NYSE:SUZ), expected to close mid-2026, further reshapes the asset base. Management has guided to organic sales growth of around 3% and double-digit adjusted EPS growth on a constant-currency basis for 2026.

What to Watch Next The stock has come back to life. Shares are up nearly 8% year to date and more than 11% over the past month, recovering from a tough trailing 12 months that saw the stock fall over 15%. The analyst target sits at $114.80, modest upside from current levels, and the consensus skews toward Hold with nine Hold ratings against six Buy or Strong Buy ratings and just one Sell rating.

For retirees, the key signal posts are clear. First, watch full-year free cash flow coverage restore above 1.2x as the elevated capex cycle normalizes. Second, watch the Kenvue integration cadence for evidence that combined cash flow can fund a larger dividend base. Third, keep an eye on the quarterly raise in early 2027. A skipped or token increase would break the rhythm in a way the bond market would notice immediately.

The 80% payout headline is doing more rhetorical work than the underlying numbers justify. A company actively deleveraging, growing equity at double-digit rates, beating earnings four quarters in a row, and operating in categories with documented stable demand is a Dividend Aristocrat navigating a heavy CapEx cycle while keeping the streak intact.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Kimberly-Clark didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.